Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2014

Open Access 01-12-2014 | Primary research

miR-22 is down-regulated in esophageal squamous cell carcinoma and inhibits cell migration and invasion

Authors: Chao Yang, Siqing Ning, Zhaoyuan Li, Xiaomin Qin, Wei Xu

Published in: Cancer Cell International | Issue 1/2014

Login to get access

Abstract

Background

Esophageal squamous cell carcinoma (ESCC) is one of the most common and deadly forms of cancer. Despite advances in the diagnosis and treatment of this cancer, the survival rate at five years is poor. Lately, miR-22 is identified as a tumor-suppressing microRNA in many human cancers. However, the specific function of miR-22 in ESCC is unclear at this point.

Methods

We first measured miR-22 expression level in 30 paired of ESCC and matched normal tissues, ESCC cell lines by real-time quantitative RT-PCR. Invasion assay, MTT proliferation assay and wound-healing assay were performed to test the invasion and proliferation of ESCC cell after overexpression of miR-22.

Results

We found that the expression of miR-22 in ESCC tissues and cell lines were much lower than that in normal control, respectively. The expression of miR-22 was inversely correlated with ESCC metastatic ability. Furthermore, transfection of miR-22 expression plasmid could significantly inhibit the cell proliferation, migration and invasion in Eca109 and Kyse410 ESCC cell lines.

Conclusions

Our findings suggest that miR-22 act as tumor suppressor and inhibiting ESCC cell migration and invasion. The findings of this study contribute to the current understanding of the functions of miR-22 in ESCC.
Appendix
Available only for authorised users
Literature
1.
Matsushima K, Isomoto H, Kohno S, Nakao K: MicroRNAs and esophageal squamous cell carcinoma. Digestion. 2010, 82 (3): 138-144. 10.1159/000310918.CrossRefPubMed
2.
Mathe EA, Nguyen GH, Bowman ED, Zhao Y, Budhu A, Schetter AJ, Braun R, Reimers M, Kumamoto K, Hughes D, Altorki NK, Casson AG, Liu CG, Wang XW, Yanaihara N, Hagiwara N, Dannenberg AJ, Miyashita M, Croce CM, Harris CC: MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res. 2009, 15 (19): 6192-6200. 10.1158/1078-0432.CCR-09-1467.CrossRefPubMedCentralPubMed
3.
Feber A, Xi L, Pennathur A, Gooding WE, Bandla S, Wu M, Luketich JD, Godfrey TE, Litle VR: MicroRNA prognostic signature for nodal metastases and survival in esophageal adenocarcinoma. Ann Thorac Surg. 2011, 91 (5): 1523-1530. 10.1016/j.athoracsur.2011.01.056.CrossRefPubMedCentralPubMed
4.
Su M, Liu M, Tian DP, Li XY, Zhang GH, Yang HL, Fan X, Huang HH, Gao YX: Temporal trends of esophageal cancer during 1995-2004 in Nanao Island, an extremely high-risk area in China. Eur J Epidemiol. 2007, 22 (1): 43-48. 10.1007/s10654-006-9086-x.CrossRefPubMed
5.
Enzinger PC, Mayer RJ: Esophageal cancer. N Engl J Med. 2003, 349 (23): 2241-2252. 10.1056/NEJMra035010.CrossRefPubMed
6.
Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB: Prediction of mammalian microRNA targets. Cell. 2003, 115 (7): 787-798. 10.1016/S0092-8674(03)01018-3.CrossRefPubMed
7.
Xiong J, Du Q, Liang Z: Tumor-suppressive microRNA-22 inhibits the transcription of E-box-containing c-Myc target genes by silencing c-Myc binding protein. Oncogene. 2010, 29 (35): 4980-4988. 10.1038/onc.2010.241.CrossRefPubMed
8.
Bar N, Dikstein R: miR-22 forms a regulatory loop in PTEN/AKT pathway and modulates signaling kinetics. PLoS One. 2010, 5 (5): e10859-10.1371/journal.pone.0010859.CrossRefPubMedCentralPubMed
9.
Ting Y, Medina DJ, Strair RK, Schaar DG: Differentiation-associated miR-22 represses max expression and inhibits cell cycle progression. Biochem Biophys Res Commun. 2010, 394 (3): 606-611. 10.1016/j.bbrc.2010.03.030.CrossRefPubMed
10.
Tsuchiya N, Izumiya M, Ogata-Kawata H, Okamoto K, Fujiwara Y, Nakai M, Okabe A, Schetter AJ, Bowman ED, Midorikawa Y, Sugiyama Y, Aburatani H, Harris CC, Nakagama H: Tumor suppressor miR-22 determines p53-dependent cellular fate through post-transcriptional regulation of p21. Cancer Res. 2011, 71 (13): 4628-4639. 10.1158/0008-5472.CAN-10-2475.CrossRefPubMed
11.
Kong LM, Liao CG, Zhang Y, Xu J, Li Y, Huang W, Zhang Y, Bian H, Chen ZN: A regulatory loop involving miR-22, Sp1, and c-Myc Modulates CD147 expression in breast cancer invasion and metastasis. Cancer Res. 2014, 74 (14): 3764-3778. 10.1158/0008-5472.CAN-13-3555.CrossRefPubMed
12.
Lin Y, Totsuka Y, He Y, Kikuchi S, Qiao Y, Ueda J, Wei W, Inoue M, Tanaka H: Epidemiology of esophageal cancer in Japan and China. J Epidemiol. 2013, 23 (4): 233-242. 10.2188/jea.JE20120162.CrossRefPubMed
13.
Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D, Mayer R: Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008, 26 (7): 1086-1092. 10.1200/JCO.2007.12.9593.CrossRefPubMed
14.
Zhang J, Yang Y, Yang T, Liu Y, Li A, Fu S, Wu M, Pan Z, Zhou W: microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity. Br J Cancer. 2010, 103 (8): 1215-1220. 10.1038/sj.bjc.6605895.CrossRefPubMedCentralPubMed
15.
Oue N, Aung PP, Mitani Y, Kuniyasu H, Nakayama H, Yasui W: Genes involved in invasion and metastasis of gastric cancer identified by array-based hybridization and serial analysis of gene expression. Oncology. 2005, 69 (Suppl 1): 17-22. 10.1159/000086627.CrossRefPubMed
16.
Gupta GP, Massague J: Cancer metastasis: building a framework. Cell. 2006, 127 (4): 679-695. 10.1016/j.cell.2006.11.001.CrossRefPubMed
17.
Klein CA: Cancer. The metastasis cascade. Science. 2008, 321 (5897): 1785-1787. 10.1126/science.1164853.CrossRefPubMed
18.
Sreekumar R, Sayan BS, Mirnezami AH, Sayan AE: MicroRNA control of invasion and metastasis pathways. Front Genet. 2011, 2: 58-10.3389/fgene.2011.00058.CrossRefPubMedCentralPubMed
19.
Andl CD, Mizushima T, Nakagawa H, Oyama K, Harada H, Chruma K, Herlyn M, Rustgi AK: Epidermal growth factor receptor mediates increased cell proliferation, migration, and aggregation in esophageal keratinocytes in vitro and in vivo. J Biol Chem. 2003, 278 (3): 1824-1830. 10.1074/jbc.M209148200.CrossRefPubMed
20.
Li H, Zheng D, Zhang B, Liu L, Ou J, Chen W, Xiong S, Gu Y, Yang J: Mir-208 promotes cell proliferation by repressing SOX6 expression in human esophageal squamous cell carcinoma. J Transl Med. 2014, 12 (1): 196-10.1186/1479-5876-12-196.CrossRefPubMedCentralPubMed
21.
Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001, 25 (4): 402-408. 10.1006/meth.2001.1262.CrossRefPubMed
22.
Liao CG, Kong LM, Song F, Xing JL, Wang LX, Sun ZJ, Tang H, Yao H, Zhang Y, Wang L, Wang Y, Yang XM, Li Y, Chen ZN: Characterization of basigin isoforms and the inhibitory function of basigin-3 in human hepatocellular carcinoma proliferation and invasion. Mol Cell Biol. 2011, 31 (13): 2591-2604. 10.1128/MCB.05160-11.CrossRefPubMedCentralPubMed
23.
Patel JB, Appaiah HN, Burnett RM, Bhat-Nakshatri P, Wang G, Mehta R, Badve S, Thomson MJ, Hammond S, Steeg P, Liu Y, Nakshatri H: Control of EVI-1 oncogene expression in metastatic breast cancer cells through microRNA miR-22. Oncogene. 2011, 30 (11): 1290-1301. 10.1038/onc.2010.510.CrossRefPubMed
Metadata
Title
miR-22 is down-regulated in esophageal squamous cell carcinoma and inhibits cell migration and invasion
Authors
Chao Yang
Siqing Ning
Zhaoyuan Li
Xiaomin Qin
Wei Xu
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2014
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-014-0138-0

Other articles of this Issue 1/2014

Cancer Cell International 1/2014 Go to the issue

Primary research

Human umbilical cord mesenchymal stem cells promote carcinoma growth and lymph node metastasis when co-injected with esophageal carcinoma cells in nude mice

Primary research

Experimental study on the regulation of erlotinib-induced radiosensitization with an anti-c-MET monoclonal antibody

Primary research

Silencing of ETS1 reverses adriamycin resistance in MCF-7/ADR cells via downregulation of MDR1

Review

Rutin mediated targeting of signaling machinery in cancer cells

Primary research

Chemotherapy induced microsatellite instability and loss of heterozygosity in chromosomes 2, 5, 10, and 17 in solid tumor patients

Primary research

Abnormal expression of CDK11p58 in prostate cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits